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Purpose/Objective: The XRAD225Cx is a small animal radiotherapy 
device using a medium energy beam (225 kVp) and small circular 
fields. In addition to the half-value layers and the absolute dose rate, 
the commissioning of this equipment requires relative dose 
measurements such as percentage depth dose (PDD), Output Factor 
(OF) and Tissue Maximum Ratio (TMR). The aim of this study was to 
compare two media and four detectors to determine the optimal 
conditions to perform these relative measurements. 
Materials and Methods: RW3 material is known not to be water-
equivalent at medium energy for absolute dose measurements. To 
evaluate the impact of this medium for relative dose measurements, 
PDDs were obtained in water and RW3 for a 10x10 cm2 field with a 
plane-parallel ionization chamber and EBT2 Gafchromic films. 
Simulated PDDs were generated using a GATE Monte Carlo model of 
the irradiator. To study the influence of the detector, four dosimeters 
(an IBA SFD diode, a PTW PinPoint 31014 microchamber, EBT2 films 
and a PTW-23342 plane-parallel chamber) were compared for OFs, 
PDDs and TMRs in water and/or RW3 depending on the dosimeter 
sealing. Measurements were performed in small fields (20, 15, 10, 8, 5 
and 2.5 mm in diameter). OFs, PDDs, and TMRs were also computed 
with the Monte Carlo model.  
Results: Measured and simulated PDDs were similar in water and RW3. 
Regardless of media and detectors, simulated and measured OFs 
showed no differences down to a diameter beam of 5 mm. For the 
smallest beam (2.5 mm),ionization chambers yielded large 
discrepancies (up to -22%) compared to SFD and EBT2 measurements 
and Monte Carlo simulations. This is due to the size of the sensitive 
volume of chambers compared to beam diameter. For PDDs and TMRs, 
measurement accuracy depends on spatial resolution in depth of the 
detector. Therefore, PinPoint chamber was not used. Plane ionization 
chamber and film measurements were closed to Monte Carlo 
computed results. SFD diode results showed significant discrepancies 
(up to 9%) due to the important variation in the relative energy 
response of the diode at 225 kVp. 
Conclusions: For relative measurements, RW3 can be used instead of 
water at 225 kVp for convenient considerations. For OFs, all studied 
detectors may be used down to a beam diameter of 5 mm. For smaller 
beams, measurements should be performed with the SFD diode or 
Gafchromic films. For PDDs and TMRs, plane ionization chamber can 
be used down to a beam diameter of 5 mm. Gafchromic films are 
suitable whatever the beam diameter.  
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Purpose/Objective: To assess the sensitivity of three different 
commercially available dosimetry systems in detecting treatment 
delivery errors during helical tomotherapy pre-treatment verification. 
Materials and Methods: Three dosimeters 1) MatriXX Evolution (IBA®) 
with OmniPro-ImRT software 2) ArcCheck®(Sun Nuclear®) with SNC 
Patient software 3) EDR-2 film with cheese phantom and RIT software 
were considered. A head and neck helical tomotherapy plan was 
edited to introduce known systematic errors in couch speed, gantry 
speed, gantry start angle, and projection time. The magnitude of each 
introduced error was +2% and +4% relative to the original treatment 
plan. All measurements were performed at the same time to minimize 
day-to-day and phantom setup variations. For each dosimeter the 
measured dose for the original plan was compared to each altered 
plan with a Gamma analysis using 3%/3 mm pass criteria. 
Results: The gamma pass rates are shown in Table 1. In each case an 
introduced error resulted in a decreased gamma pass rate. Results 
were comparable across the three detectors. Sensitivity to couch 
speed, gantry speed, and start gantry angle were similar for each 
detector. All detectors were most sensitive to projection time errors. 
 
Conclusions: All three dosimetry systems were sensitive to each 
introduced error. Additional work is underway to assess the impact of 
these errors on treatment plans and to include systematic/random 
error in MLC and jaw position. This work will also help to establish 
meaningful tolerance levels for quality assurance. 
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Purpose/Objective: To evaluate the accuracy of the dose calculation 
algorithm for the target (bones) and some sensitive structures (lungs, 
eyes, heart, kidneys) in total marrow irradiation (TMI) performed with 
helical tomotherapy (HT). 
Materials and Methods: Thermoluminescent detectors (TLDs) were 
used to measure delivered doses. Dose optimization was performed 
with the HT treatment planning system. Doses were calculated for 
selected points in the target - bones (9 TLDs), in the central lung (11 
TLDs) and in eye, heart, kidney (4 TLDs) in an anthropomorphic 
phantom. The target dose was 12 Gy to the skeletal bone. A dose of 2 
Gy was delivered 6 times. We compared the calculated dose to the 
measured dose. 
Results: For each dosimetric point, the measured value was averaged 
and corrected by the MVCT scan value and converted according to the 
calibration factors. The mean difference between the measured and 
calculated dose for the bone TLDs was 1.2% (with a range of -4.2% to 
+5.0% for individual detectors included in this group), indicating that 
the measured dose was higher than the calculated dose. For the lung-
TLD group of detectors, the corresponding difference was -1.9% 
(range, -9.0% to +7.6%). At 11 points, the measured dose was lower 
than the calculated dose, with the largest differences observed in the 
region located in the kidney (-9.2%) and lungs (-9.0%).  
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Point 
Measured 
Dose 
[Gy] 
Calculated 
Dose [Gy] 
Percentage 
Difference 
[%] 
Point 
Measured 
Dose 
[Gy] 
Calculated
Dose [Gy] 
Percentage 
Difference 
[%] 
Eye 0.435 0.404 7.2 Kidney 1 0.321 0.350 -9.2 
Heart0.740 0.757 -2.3 Kidney 2 0.345 0.366 -6.1 
Bone 
1 2.054 2.039 0.7 Lung 1 0.901 0.936 -4.0 
Bone 
2 2.046 2.024 1.1 Lung 2 1.063 1.116 -5.1 
Bone 
3 2.102 1.997 5.0 Lung 3 0.464 0.492 -6.2 
Bone 
4 2.058 2.018 1.9 Lung 4 0.573 0.584 -2.0 
Bone 
5 2.079 2.007 3.5 Lung 5 0.531 0.545 -2.7 
Bone 
6 1.997 1.996 0.1 Lung 6 0.661 0.611 7.6 
Bone 
7 1.995 1.993 0.1 Lung 7 0.593 0.641 -8.1 
Bone 
8 1.979 2.062 -4.2 Lung 8 0.894 0.829 7.3 
Bone 
9 2.042 1.988 2.6 Lung 9 0.515 0.531 -3.0 
    
Lung 
10 0.518 0.564 -9.0 
    
Lung 
11 0.575 0.553 3.9 
 
Conclusions: The mean measured dose to the lungs was only 6.02 Gy, 
whereas most studies of TBI have reported a range of 8-10 Gy. TMI-HT 
delivers lower doses vs. conventional total body irradiation, thus 
providing additional support for this technique. HT-TMI reduces the 
dose delivered to the lungs to levels that are much lower than those 
reported for TBI with a conventional linear accelerator. These results 
provide additional support for the use of TMI in conditioning regimens 
for bone marrow transplantation.  
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Purpose/Objective: Portal Dosimetry (PD) is a convenient tool for 
rapid and reliable pre-treatment verification of IMRT and VMAT plans. 
Varian's PD solution requires commissioning of a dedicated prediction 
algorithm as well as the calibration of the amorphous Silicon (aSi) 
imager. These procedures involve the individual configuration for each 
system and are limited by inherent shortcomings such as imperfect 
beam profile correction and backscatter effects. For these reasons we 
propose generic configuration data per system type and beam energy 
including improved beam profile and backscatter correction. This 
work aims for evaluating the applicability of this generic configuration 
data to different Varian aSi/Linac combinations by comparing 
predicted and acquired PD images with respect to output factor (OF), 
beam profile and backscatter correction. 
Materials and Methods: The backscatter effect is field size 
dependent, thus implementing the backscatter correction using 
calibration data required a trade-off: Good performance for small to 
medium (clinically more relevant) field sizes versus reduced 
performance for larger field sizes. The PD solution was configured on 
11 Varian systems (3 Unique, 8 Clinac) at 9 different sites for beam 
energies of 6 MV (n=8), 15 MV (n=2) and 18MV (n=3) using the generic 
PD configuration package. Pre-treatment verification plans were 
created to calculate predicted PD images for square fields of size 3 x 
3 cm2 to 30 x 30 cm2. Subsequently, the corresponding PD images 
were acquired. 
Performance of the configured PD solution was evaluated with respect 
to: (i) OFs by calculating the rel. difference (acquired vs. predicted 
PD image) of the central axis dose values, (ii) beam profile correction 
by calculating the mean rel. difference of the central cross-line 
profiles in the flat field region (80% area within field limits) and (iii) 
backscatter correction by calculating the maximum rel. difference of 
the central half in-line profile in the flat field region (Fig. 1a). 
 
  
Results: The analysis of 6MV Clinac data (Fig. 1b) revealed that for 
OFs and beam profile correction the rel. differences were found to be 
within ±1% for all field sizes, while the backscatter correction was 
found to be within ±1.5% for field sizes up to 15 x 15 cm2. For the 6MV 
Unique data and 15MV Clinac data the same limits were met except 
for the backscatter correction of the smallest field size (3 x 3 cm2). 
The 18MV Clinac data revealed rel. differences smaller than ±1% for 
both OFs and beam profile correction, while not all field sizes (4 x 4 
cm2 and 5 x 5 cm2) met the ±1.5% limit for the backscatter correction. 
Conclusions: The use of generic configuration data appears to be 
feasible for the Varian PD solution allowing for a simplified 
configuration process and the easy implementation of essential 
improvements. Further data at high beam energies as well as for 
dynamic MLC fields (IMRT and VMAT) are required to support the 
promising results obtained in this preliminary study. 
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Purpose/Objective: To evaluate the possibility to use an amorphus 
silicon portal imager as pre-treatment quality assurance of RapidArc 
plans with flattening filter free (FFF) beams. 
Materials and Methods: On Varian TrueBeam linac, the PV-aS1000 
detector response was investigated for 6 and 10 MV FFF beams. With 
an adequate source to detector distance, e.g. SDD=150 cm, even with 
the maximum dose rate of 1400 and 2400 MU/min the integrated 
image does not present saturation. This allows its usage for dosimetric 
evaluations also for FFF beams. The GLAaS algorithm was originally 
developed to convert portal imager integrated readings into absorbed 
dose to water, and was validated for IMRT and RapidArc (the Varian 
VMAT) pre-treatment quality assurance for standard flattened beams. 
The algorithm was adapted to FFF beams and validated for open as 
well as for modulated beams. In this study it was used to evaluate 
RapidArc pre-treament acquisitions. Five different clinical FFF 
RapidArc plans were selected and recalculated for both 6 and 10 MV 
FFF. The maximum dose rate was set for each energy. Dose 
prescriptions ranged from 7 to18 Gy/fraction. Pre-treatment QA 
deliveries were performed on four different TrueBeam machines (two 
equipped with a high-definition MLC, HD-120MLC, and two with a 
standard Millenium 120-MLC). QA evaluation was based on gamma 
index,using distance to agreement and dose difference criteria of 
3mm/3% and 2mm/2%. 2D dose maps were evaluated also through 
profiles. 
Results: The percentage of points passing the gamma criteria (gamma 
agreement index GAI) were collected for all deliveries.For 3mm/3% 
criteria, GAI evaluated on the field area was 97.9±2.5% and and 
98.6±1.6% for 6 and10 MV FFF respectively.For 2mm/2% criteria, GAI 
evaluated on the field area was 92.0±3.5% and and 96.6±4.3% for 6 
and10 MV FFF respectively. 
Conclusions: The possibility to use the Portal Vision as pre-treatment 
QA for RapidArc for FFF beams gives advantages that can be 
summarised in three points: 1) verification of absorbed dose 
calculation, 2) fast acquisition, 3) improved resolution at SDD=150 cm, 
particularly interesting in hypofractionated treatment, where small 
fields are mostly used. Gamma results presented fully satisfactory 
results in line with standard flattened beams.  
